Skip to main content

Table 2 Characteristics of DESIR patients satisfying selected criteria sets

From: Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

  Canada n = 169 France n = 197 UK n = 86 Germany n = 175 Hong Kong n = 61
Anti-TNF non-user (n = 98) Anti-TNF user (n = 71) Anti-TNF non-user (n = 117) Anti-TNF user (n = 80) Anti-TNF non-user (n = 46) Anti-TNF user (n = 40) Anti-TNF non-user (n = 108) Anti-TNF user (n = 67) Anti-TNF non-user (n = 29) Anti-TNF user (n = 32)
At baseline
 Age 32.8 ± 8.5 33.5 ± 9.3 33.2 ± 8.7 33 ± 9.1 33 ± 7.6 32.6 ± 9.6 32.7 ± 7.9 33.1 ± 9.4 35 ± 8 31.8 ± 8.5
 Male 53 (54.1%) 40 (56.3%) 58 (49.6%) 59 (53.8%) 27 (58.7%) 24 (60%) 59 (54.6%) 37 (55.2%) 17 (58.6%) 19 (59.4%)
 Post-secondary education 55 (56.1%) 42 (59.2%) 65 (55.6%) 48 (60%) 22 (47.8%) 20 (50%) 60 (55.6%) 35 (59.7%) 11 (37.9%) 14 (43.8%)
 Married 58 (59.2%) 40 (59.2%) 71 (60.7%) 48 (60%) 24 (52.2%) 23 (57.5%) 69 (63.9%) 40 (59.7%) 17 (58.6%) 19 (59.4%)
 Smoking 41 (41.8%) 36 (50.7%) 50 (42.7%) 38 (47.5%) 23 (50.0%) 22 (55.0%) 44 (40.7%) 35 (52.2%) 12 (41.4%) 19 (59.4%)
 Disease duration 1.5 ± 0.9 1.6 ± 0.8 1.6 ± 0.9 1.6 ± 0.8 1.7 ± 0.9 1.6 ± 0.8 1.5 ± 0.9 1.6 ± 0.8 1.7 ± 0.9 1.6 ± 0.8
 Peripheral Arthritis 54 (55.1%) 49 (69%) 65 (55.6%) 55 (68.8%) 22 (47.8%) 25 (62.5%) 56 (51.9%) 46 (68.7%) 13 (44.8%) 21 (65.6%)
 HLA-B27: positive 59 (60.2%) 44 (62%) 66 (56.4%) 48 (60%) 32 (69.6%) 25 (62.5%) 83 (76.9%) 46 (68.7%) 18 (62.1%) 19 (59.4%)
 Radiographic sacroiliitis 42 (42.9%) 40 (56.3%) 49 (41.9%) 44 (55.0%) 28 (60.9%) 30 (75.0%) 49 (45.4%) 41 (61.2%) 15 (51.7%) 25 (78.1%)
 Sacroiilitis or spine inflammation on MRI 67 (68.4%) 49 (69.0%) 67 (57.3%) 49 (61.3%) 25 (54.3%) 26 (65.0%) 80 (74.1%) 52 (77.6%) 12 (41.4%) 21 (65.6%)
 BASDAI ≥ 4 74 (75.5%) 67 (94.4%) 91 (77.8%) 76 (95.0%) 34 (73.9%) 39 (97.5%) 78 (72.2%) 62 (92.5%) 21 (72.4%) 31 (96.9%)
 CRP > 10 mg/L 24 (24.5%) 31 (43.7%) 25 (21.4%) 33 (41.3%) 8 (17.4%) 21 (52.5%) 26 (24.1%) 32 (47.8%) 5 (17.2%) 14 (43.8%)
 Physician’s global assessment ≥4 76 (77.6%) 66 (93.0%) 92 (78.6%) 75 (93.8%) 33 (71.7%) 38 (95.0%) 73 (67.6%) 61 (91.0%) 20 (69.0%) 31 (96.9%)
 Inflammatory back pain ≥ 4 79 (80.6%) 68 (95.8%) 96 (82.1%) 76 (95.0%) 40 (87.0%) 40 (100%) 88 (81.5%) 64 (95.5%) 25 (86.2%) 32 (100%)
 Morning stiffness ≥45 min 53 (54.1%) 47 (66.2%) 62 (53.0%) 56 (70.0%) 20 (43.5%) 31 (77.5%) 57 (52.8%) 47 (70.1%) 18 (62.1%) 30 (93.8%)
 Patient global assessment ≥4 73 (74.5%) 65 (91.5%) 88 (75.2%) 74 (92.5%) 33 (71.7%) 38 (95.0%) 79 (73.1%) 60 (89.6%) 23 (79.3%) 31 (96.9%)
At criteria satisfaction
 BASDAI 56.2 ± 12.7 60.6 ± 11.4 55.4 ± 12.2 60.9 ± 10.9 52.8 ± 10.5 58.9 ± 11.9 55.5 ± 12.7 58.7 ± 10.8 56.1 ± 12 59.3 ± 11.7
 BASFI 35.8 ± 21.8 43.9 ± 20.2 35.9 ± 21.5 45 ± 19.8 30.8 ± 20 47.4 ± 20.8 36.5 ± 23.5 42.1 ± 19.7 39 ± 21.6 46.5 ± 22
 SF-36 0.6 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 0.5 ± 0.1
 Physician’s global assessment 5.3 ± 1.2 6.7 ± 1.6 5.3 ± 1.2 6.8 ± 1.5 4.7 ± 1.7 6.8 ± 1.7 4.5 ± 1.8 6.4 ± 2 5 ± 1.6 6.7 ± 1.6
 CRP 10.9 ± 18.6 20.1 ± 24.6 9.5 ± 17.2 18.8 ± 23.8 7.7 ± 9.3 22.3 ± 25.5 10.9 ± 12.5 19.7 ± 23.7 7.6 ± 10.2 15.8 ± 20.6
  1. Statistics presented are: Mean ± SD, or N (%)